Evidence map›Paper›PMID 41323796›Full record

ArticleMolecular therapy. Nucleic acids2025

SCAD: A modular platform for efficient delivery of duplex RNA to the CNS and beyond.

Moorim Kang, Wei-Hsiang Lin, Yichen Li, Feifei Xu, Xiaojie Zhou, Chunyan Si, Jianxiu Dai, Jichao He, Ian Schacht, Zubao Gan and 2 more

Abstract read
In one paragraph

Article in Molecular therapy. Nucleic acids, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Moorim KangRactigen Therapeutics, Nantong, Jiangsu, China.
Wei-Hsiang LinRactigen Therapeutics, Nantong, Jiangsu, China.
Yichen LiRactigen Therapeutics, Nantong, Jiangsu, China.
Feifei XuRactigen Therapeutics, Nantong, Jiangsu, China.
Xiaojie ZhouRactigen Therapeutics, Nantong, Jiangsu, China.
Chunyan SiRactigen Therapeutics, Nantong, Jiangsu, China.
Jianxiu DaiRactigen Therapeutics, Nantong, Jiangsu, China.
Jichao HeRactigen Therapeutics, Nantong, Jiangsu, China.
Ian SchachtRactigen Therapeutics, Nantong, Jiangsu, China.
Zubao GanRactigen Therapeutics, Nantong, Jiangsu, China.
Vera HuangRactigen Therapeutics, Nantong, Jiangsu, China.
Long-Cheng LiRactigen Therapeutics, Nantong, Jiangsu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oligonucleotide therapeutics-including antisense oligonucleotides and duplex RNAs such as small interfering RNAs, small activating RNAs, and microRNAs-hold immense potential for treating both genetic and acquired diseases by modulating gene expression in a target-specific manner. However, effective delivery to extrahepatic tissues, particularly the central nervous system, remains a significant challenge. While

Indexed as

CNSdeliveryMT: Oligonucleotides: Therapies and Applicationsoligonucleotide therapeuticsSCADsiRNASOD1-ALS

Identifiers

PMID41323796
PMCPMC12663631

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.